PA Supreme Court Upholds $70 Million Risperdal Verdict
The Pennsylvania Supreme Court has denied Johnson & Johnson’s request to overturn the $70 million Risperdal verdict upheld by a Superior court panel of judges last year. The case, A.Y. v. Janssen Pharmaceuticals, will now be remanded back to the PA Court of Common Pleas for a second trial to reconsider punitive damages. “We are […]
$8 Billion Risperdal Verdict Tops Legal News in 2019
April 2020 Update: Stephen Sheller has been recognized by the American Association for Justice with AAJ’s 2019 Top Verdict Award. “Each year, American Association for Justice releases the Top Verdicts Litigation Packet, featuring the opening statements and closing arguments from the previous year’s top cases. Congratulations on the impressive result you secured for your clients […]
Risperdal Case Reinstated After Janssen Appeal Denied
The Pennsylvania Supreme Court declined to hear Janssen Pharmacuetical’s request for an appeal of a lower courts decision to reinstate the lawsuit of a Texas man who took Risperdal as a child. The Pennsylvania Superior Court’s decision to allow Tommy Moroni’s suit against Janssen, a subsidiary of Johnson & Johnson, to go back to trial will stand. July 2019, the Pennsylvania […]
Plaintiff’s Counsel Vows to Have $8B Risperdal Verdict Reinstated
Philadelphia Court of Common Pleas Judge Kenneth Powell reduced an October 2019 $8 billion punitive damages verdict against J&J to $6.8 million. A jury had awarded the figure over allegations that J&J’s drug Risperdal caused the plaintiff to grow breasts as a young boy. The $6.8 million reduced verdict is 10 times the jury verdict […]
Superior Court Upholds $70M Risperdal Verdict
A Pennsylvania Superior Court has rejected Johnson & Johnson’s appeal of a 2016 $70 million verdict awarded to a 20 year-old Tennessee man, Andrew Yount (A.Y.) who developed gynecomastia after taking the antipsychotic drug Risperdal since he was 4-1/2 years old. Gynecomastia is an irreversible condition caused by an increase in the hormone prolactin and […]
Thousands of Risperdal Cases Previously Time-Barred, Reopened
In a 6 to 1 decision, the Pennsylvania Supreme Court opened the door for thousands of pending Risperdal injury cases to proceed to trial. The seven-justice court ruled that a jury must decide, on a case by case basis, at which date the plaintiff should have had knowledge that the ingestion of Janssen Pharmaceuticals drug […]
$8 Billion Verdict: Jury decides J&J should pay in Risperdal case
October 9, 2019: Late yesterday a Philadelphia jury rendered an $8 billion punitive damages verdict against pharmaceutical company Johnson & Johnson for illegally marketing the antipsychotic drug Risperdal, putting young boys at risk for developing female-sized breast tissue. The condition, gynecomastia, is irreversible. “The conduct the jury saw in the courtroom was clear and convincing that J&J disregarded the […]
J&J CEO May Testify in Risperdal Trial
Updated January 30, 2019 The eighth Risperdal case is set to go to trial, this time the stakes are even higher for both sides as the jury may award punitive damages to the plaintiff if wrongful conduct by Johnson & Johnson is proven. “We’re excited about the availability of punitive damages. All along, we thought […]
$2.5 M Risperdal Verdict Upheld in Superior Court
The Pennsylvania Superior Court has upheld the 2015 $2.5 million Risperdal verdict for plaintiff Austin Pledger. Pledger’s case was the first Risperdal case to go to trial. Viewed as a huge win for plaintiffs, the decision bodes well for the future litigation of 6,500 plaintiffs whose suits against Janssen Pharmaceutical, a subsidiary of Johnson & […]
J&J Settles Days Before Risperdal Trial
After years of litigation and several court losses for harm caused by Risperdal, Johnson & Johnson’s legal team agreed to settle the suit of a young boy from Mississippi who claims he developed female-like breasts after taking the drug Risperdal. The plaintiff began taking Risperdal in 2004 after he was tentatively diagnosed with bipolar disorder. J&J […]
